Maegim한국어

진바이오텍

086060KOSDAQSector: Retail & Consumer Services
₩5,150▲ 0.78%Market cap ₩44.3BAs of Jul 21, 2026 close · updated once daily
A
Grade A64.7 ptsTop 22% of 2,523 stocks
Financial strength
74.8
Growth momentum
68.1
Price attractiveness
50.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

74.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
37.5%
✓ Above median · Top 28.3% in sector
Sector median 78.3%
Can it cover what's due within a year?
Current ratio
348.2%
✓ Above median · Top 18.2% in sector
Sector median 147.9%
How much of revenue becomes profit?
Operating margin
4.3%
✓ Above median · Top 28.3% in sector
Sector median 1.3%
How much did it earn on its own capital?
ROE (return on equity)
6.9%
✓ Above median · Top 26% in sector
Sector median 2.1%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

68.1
How much did revenue grow in a year?
Revenue growth (YoY)
9.4%
✓ Above median · Top 24.4% in sector
Sector median 1.0%
Has it grown steadily over three years?
Revenue 3-year CAGR
3.1%
✓ Above median · Top 35.9% in sector
Sector median -1.5%
Did core profits grow in a year?
Operating income change (YoY)
2.0%
✗ Below median · Top 53.4% in sector
Sector median 7.8%
Are core profits higher than three years ago?
Operating income change (3Y)
134.8%
✓ Above median · Top 13.8% in sector
Sector median 3.9%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

50.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
11.7x
✓ Above median · Top 33.8% in sector
Sector median P/E of profitable peers 10.4x · 40% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.81x
✗ Below median · Top 64.6% in sector
Sector median 0.57x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 168 stocks in Retail & Consumer Services

S2A30B60C30D33F13